Circulating apelin, chemerin and omentin levels in patients with gestational diabetes mellitus: a systematic review and meta-analysis

Sun, Jianran; Ren, Jiale; Zuo, Chunlin; Deng, Datong; Pan, Faming; Chen, Ruoping; Zhu, Jie; Chen, Chao; Ye, Shandong

doi:10.1186/s12944-020-01209-7

Lipids in Health and Disease

Table 1 Characteristics of studies investigating circulating apelin, chemerin and omentin levels in GDM

From: Circulating apelin, chemerin and omentin levels in patients with gestational diabetes mellitus: a systematic review and meta-analysis

					Cases				Controls
First authors	Year	Country	Study type	N	Age (years), mean ± SD	Gestational BMI(kg/m²)	Mean ± SD(ng/mL)/(ng/mL)	N	Age (years), mean ± SD	Gestational BMI(kg/m²)	Mean ± SD(ng/mL)/(ng/mL)	P	Criteria for GDM	Measurement	NOS
Apelin
Baris [11]	2014	Turkey	Cohort	141	35.18 ± 5.55	26.82 ± 4.25	0.33 ± 0.18	49	34.89 ± 5.64	26.50 ± 2.66	0.56 ± 0.29	< 0.001	ADA	ELISA system)	7
Mehmet [6]	2012	Turkey	CC	30	30.90 ± 4.20	25.90 ± 3.30	13.50 ± 9.30	30	31.00 ± 3.20	25.70 ± 2.80	9.60 ± 5.90	0.001	ACOG	ELISA	8
Emel [12]	2016	Turkey	Cohort	20	28.95 ± 6.21	27.95 ± 4.19	2.29 ± 0.39	20	27.00 ± 1.20	27.05 ± 4.05	0.91 ± 0.32	< 0.001	ACOG	ELISA	6
Oncul [7]	2013	Turkey	CC	24	34.00 ± 7.00	31.32 ± 5.82	0.15 ± 0.05	21	30.00 ± 4.00	29.32 ± 4.53	0.16 ± 0.09	0.602	C&C	ELISA	7
Beata [4]	2010	Poland	CC	101	31.00 ± 6.02	24.57 ± 5.11	1.65 ± 0.39	101	30.00 ± 4.51	23.39 ± 4.21	1.65 ± 0.32	> 0.05	WHO	RIA	7
Beata [4]	2010	Poland	CC	20	31.65 ± 3.76	20.66 ± 4.51	1.61 ± 0.24	16	29.65 ± 5.26	25.94 ± 4.51	1.59 ± 0.49	> 0.05	WHO	RIA	7
Chemerin
Panayoula [33]	2018	Greece	CC	5	29.80 ± 1.20	26.90 ± 0.80	209.39 ± 37.60	13	30.60 ± 3.40	26.90 ± 0.60	162.27 ± 10.04	> 0.05	IADPSG	ELISA	7
Panayoula [33]	2018 Greece	Greece	CC	10	27.70 ± 1.60	36.00 ± 1.50	215.16 ± 17.19	10	36.10 ± 1.20	36.40 ± 1.80	212.81 ± 36.22	> 0.05	IADPSG	ELISA	7
Gillian [23]	2012	Australia	CC	69	35.20 ± 0.60	31.20 ± 0.90	117.60 ± 3.50	62	33.10 ± 0.60	34.80 ± 1.00	124.20 ± 4.00	> 0.05	ADIPS	ELISA	7
Boyadzhieva [5]	2013	Bulgarias	CC	127	32.20 ± 5.20	28.50 ± 6.60	6.89 ± 2.26	109	30.60 ± 4.40	28.00 ± 5.40	7.97 ± 2.42	0.009	IADPSG	ELISA	8
Syeda [26]	2017	Pakistan	CC	208	27.30 ± 5.56	24.83 ± 5.13	93.39 ± 45.43	300	25.78 ± 4.73	22.38 ± 3.93	14.35 ± 5.88	< 0.001	IADPSG	ELISA	8
Umit [27]	2016	Turkey	CS	76	27.59 ± 12.09	36.25 ± 22.21	4.53 ± 3.82	82	26.35 ± 12.833	31.10 ± 21.05	3.43 ± 1.84	0.100	ACOG	ELISA	6
Li [24]	2015	China	CC	16	29.30 ± 2.50	23.00 ± 0.40	222.00 ± 25.20	15	28.30 ± 2.40	20.90 ± 0.50	73.10 ± 8.60	< 0.05	ADA	ELISA	7
Li [24]	2015	China	CC	16	29.30 ± 3.10	27.10 ± 0.40	225.20 ± 26.80	15	29.40 ± 2.80	26.90 ± 0.30	151.00 ± 15.50	< 0.05	ADA	ELISA	7
Li [24]	2015	China	CC	16	29.14 ± 4.38	33.00 ± 0.80	136.80 ± 20.30	12	29.50 ± 4.84	33.40 ± 0.80	195.00 ± 34.40	> 0.05	ADA	ELISA	7
Liang [25]	2018	China	CC	46	31.89 ± 4.53	21.52 ± 3.38	20.11 ± 3.28	43	30.58 ± 3.77	21.06 ± 2.93	17.63 ± 3.63	0.001	ADA	ELISA	8
Sadia [16]	2018	Canada	Cohort	105	35.00 ± 4.00	25.78 ± 5.19	54.80 ± 16.00	76	35.00 ± 4.00	24.79 ± 5.21	55.80 ± 12.70	0.48	NDDG	ELISA	8
Dorte [8]	2010	Germany	CC	40	33.00 ± 10.00	24.90 ± 4.90	217.60 ± 72.30	80	28.00 ± 5.00	22.30 ± 7.00	230.30 ± 42.40	> 0.05	ADA	ELISA	8
Yang [15]	2017	China	CC	19	26.84 ± 2.95	22.74 ± 1.68	146.60 ± 38.91	20	26.84 ± 2.95	21.72 ± 1.23	187.23 ± 46.83	< 0.05	IADPSG	ELISA	7
Yang [15]	2017	China	CC	19	26.84 ± 2.95	25.67 ± 1.39	308.56 ± 56.43	20	26.84 ± 2.95	24.15 ± 1.24	227.53 ± 46.49	< 0.05	IADPSG	ELISA	7
Omentin
Panayoula [33]	2018	Greece	CC	5	29.80 ± 1.20	26.90 ± 0.80	17.69 ± 2.46	13	30.60 ± 3.40	26.90 ± 0.60	31.85 ± 6.67	< 0.05	IADPSG	ELISA	7
Panayoula [33]	2018	Greece	CC	10	27.70 ± 1.60	36.00 ± 1.50	19.20 ± 1.60	10	36.10 ± 1.20	36.40 ± 1.80	20.25 ± 3.55	< 0.05	IADPSG	ELISA	7
Aktas [28]	2014	Turkey	Cohort	36	28.60 ± 7.20	28.40 ± 13.74	304.27 ± 413.06	37	48.00 ± 8.60	27.00 ± 12.34	363.28 ± 488.19	0.001	C&C	ELISA	8
Gillian [29]	2012	Australia	Cohort	21	35.50 ± 0.80	23.20 ± 0.80	12.10 ± 1.40	27	33.10 ± 0.70	23.40 ± 0.60	19.50 ± 2.30	< 0.05	ADIPS	ELISA	8
Gillian [29]	2012	Australia	Cohort	18	34.00 ± 1.10	37.80 ± 1.50	8.20 ± 1.20	17	30.80 ± 1.10	38.60 ± 1.30	7.10 ± 0.90	> 0.05	ADIPS	ELISA	8
Emel [12]	2016	Turkey	Cohort	20	28.95 ± 6.21	27.95 ± 4.19	13.11 ± 1.79	20	27.00 ± 1.20	27.05 ± 4.05	18.64 ± 3.48	< 0.001	ACOG	ELISA	6
Marie [31]	2018	Australia	Cohort	96	34.10 ± 7.40	28.00 ± 6.60	157.00 ± 83.00	96	32.80 ± 9.30	26.30 ± 4.70	158.00 ± 93.00	0.94	ADA	ELISA	8
Marie [31]	2018	Australia	Cohort	96	34.10 ± 7.40	28.00 ± 6.60	118.00 ± 77.00	96	32.80 ± 9.30	26.30 ± 4.70	150.00 ± 89.00	0.12	ADA	ELISA	8
Lewandowski [30]	2010	Poland	CC	20	29.70 ± 5.50	28.10 ± 4.70	48.00 ± 12.00	23	28.30 ± 3.90	28.30 ± 4.80	50.20 ± 7.90	0.64	WHO	ELISA	6
RadzisBaw [32]	2018	Poland	CC	63	12.00 ± 3.87	9.43 ± 1.67	438.36 ± 373.28	55	11.09 ± 3.43	8.18 ± 1.18	528.40 ± 374.55	> 0.05	WHO	ELISA	7

N Number of studies, GDM Gestational diabetes mellitus, CC Case control, BMI Body mass index, ADA American diabetes association, ACOG American College of Obstetricians and Gynecologists;
C&C Carpenter and Couston, WHO World Health Organization, IADPSG International Association of Diabetes and Pregnancy Study Group, ADIPS Australasian Diabetes in Pregnancy Society
NDDG National Diabetes Date Group, ELASA Enzyme linked immunosorbent assay, RIA Radioimmunoassay, NOS Newcastle-Ottawa Scale

Back to article page

ISSN: 1476-511X

Contact us

General enquiries: journalsubmissions@springernature.com